Yi-Wen Huang1, Chieh-Ti Kuo2, Jo-Hsin Chen2, Paul J Goodfellow3, Tim H-M Huang4, Janet S Rader5, Denise S Uyar5. 1. Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address: ywhuang@mcw.edu. 2. Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA. 3. Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH 43210, USA. 4. Department of Molecular Medicine and Cancer Therapy & Research Center, University of Texas Health Science Center, San Antonio, TX 78229, USA. 5. Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Abstract
OBJECTIVES: Aberrant expression of SOX4 in endometrial cancer has been identified and partially was contributed to hypermethylation of miR-129-2. Other miRNAs are suspected to influence SOX 4 as well. The current study seeks to identify other hypermethylated miRNAs that regulate SOX4 in endometrial carcinomas. METHODS: Methylation levels of miRNA promoter regions were measured by combined bisulfite restriction analysis (COBRA) and pyrosequencing assays. Gene expression was determined by RT-qPCR. Methylation level of a miRNA locus was corrected with clinicopathologic factors for 252 gynecological specimens. RESULTS: In silico analysis identified 13 miRNA loci bound on the 3'-UTR of SOX4. Using COBRA assays, increased methylation of miR-203, miR-219-2, miR-596, and miR-618 was detected in endometrial cancer cells relative to those seen in a normal cell line and in normal endometrium. Transfection of a miR-203 mimic decreased SOX4 gene expression. Hypermethylation of miR-203 was detected in 52% of type I endometrioid endometrial carcinomas (n=131) but was not seen in any of 10 uninvolved normal endometria (P<0.001). Methylation status of miR-203 was significantly associated with microsatellite instability and MLH1 methylation in endometrial tumors (P<0.001). Furthermore, hypermethylation of miR-203 was found in endometrioid and clear endometrial subtype tumors, but not in cervical squamous cell and ovarian carcinomas. CONCLUSIONS: Hypermethylation of miR-203 is a frequent event in endometrial carcinomas and is strongly associated with microsatellite instability and MLH1 methylation status. Thus, miR-203 methylation level might represent a marker for patients with endometrioid and clear endometrial sub-cancers.
OBJECTIVES: Aberrant expression of SOX4 in endometrial cancer has been identified and partially was contributed to hypermethylation of miR-129-2. Other miRNAs are suspected to influence SOX 4 as well. The current study seeks to identify other hypermethylated miRNAs that regulate SOX4 in endometrial carcinomas. METHODS: Methylation levels of miRNA promoter regions were measured by combined bisulfite restriction analysis (COBRA) and pyrosequencing assays. Gene expression was determined by RT-qPCR. Methylation level of a miRNA locus was corrected with clinicopathologic factors for 252 gynecological specimens. RESULTS: In silico analysis identified 13 miRNA loci bound on the 3'-UTR of SOX4. Using COBRA assays, increased methylation of miR-203, miR-219-2, miR-596, and miR-618 was detected in endometrial cancer cells relative to those seen in a normal cell line and in normal endometrium. Transfection of a miR-203 mimic decreased SOX4 gene expression. Hypermethylation of miR-203 was detected in 52% of type I endometrioid endometrial carcinomas (n=131) but was not seen in any of 10 uninvolved normal endometria (P<0.001). Methylation status of miR-203 was significantly associated with microsatellite instability and MLH1 methylation in endometrial tumors (P<0.001). Furthermore, hypermethylation of miR-203 was found in endometrioid and clear endometrial subtype tumors, but not in cervical squamous cell and ovarian carcinomas. CONCLUSIONS: Hypermethylation of miR-203 is a frequent event in endometrial carcinomas and is strongly associated with microsatellite instability and MLH1 methylation status. Thus, miR-203 methylation level might represent a marker for patients with endometrioid and clear endometrial sub-cancers.
Authors: A Formosa; A M Lena; E K Markert; S Cortelli; R Miano; A Mauriello; N Croce; J Vandesompele; P Mestdagh; E Finazzi-Agrò; A J Levine; G Melino; S Bernardini; E Candi Journal: Oncogene Date: 2012-02-06 Impact factor: 9.867
Authors: Tak-hong Cheung; Kwun-nok Mimi Man; Mei-yung Yu; So-fan Yim; Nelson S S Siu; Keith W K Lo; Graeme Doran; Raymond R Y Wong; Vivian W Wang; David I Smith; Michael J Worley; Ross S Berkowitz; Tony K H Chung; Yick-fu Wong Journal: Cell Cycle Date: 2012-08-01 Impact factor: 4.534
Authors: J Bruch; W A Schulz; J Häussler; I Melzner; S Brüderlein; P Möller; R Kemmerling; W Vogel; H Hameister Journal: Cancer Res Date: 2000-08-15 Impact factor: 12.701
Authors: Saskia M Wilting; Wina Verlaat; Annelieke Jaspers; Nour A Makazaji; Reuven Agami; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen Journal: Epigenetics Date: 2013-01-16 Impact factor: 4.528
Authors: Yi-Wen Huang; Joseph C Liu; Daniel E Deatherage; Jingqin Luo; David G Mutch; Paul J Goodfellow; David S Miller; Tim H-M Huang Journal: Cancer Res Date: 2009-11-03 Impact factor: 12.701
Authors: A M Lena; R Shalom-Feuerstein; P Rivetti di Val Cervo; D Aberdam; R A Knight; G Melino; E Candi Journal: Cell Death Differ Date: 2008-05-16 Impact factor: 15.828
Authors: Gemma L Moir-Meyer; John F Pearson; Felicity Lose; Rodney J Scott; Mark McEvoy; John Attia; Elizabeth G Holliday; Paul D Pharoah; Alison M Dunning; Deborah J Thompson; Douglas F Easton; Amanda B Spurdle; Logan C Walker Journal: Hum Genet Date: 2014-11-09 Impact factor: 4.132